CANCER AND LEUKEMIA GROUP B--MOUNT SINAI

癌症和白血病 B 组——西奈山

• 批准号: 2601176
• 负责人: JAMES F HOLLAND
• 金额: $ 3.39万
• 依托单位: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
• 依托单位国家: 美国
• 财政年份: 1979
• 资助国家: 美国
• 起止时间: 1979-04-01 至 2001-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2601176
• 关键词: AIDS related neoplasm /cancer; aging; antineoplastics; bone marrow transplantation; breast neoplasms; cancer prevention; cancer registry /resource; carmustine; chemoprevention; cis platinum compound; clinical research; clinical trials; combination cancer therapy; combination chemotherapy; cooperative study; cyclophosphamide; doxorubicin; drug resistance; finasteride; fluorouracil; gastrointestinal neoplasms; health care cost /financing; hormone therapy; human genetic material tag; human subject; human therapy evaluation; interleukin 2; leucovorin; leukemia; lymphoma; melanoma; neoplasm /cancer chemotherapy; neoplasm /cancer diagnosis; neoplasm /cancer epidemiology; neoplasm /cancer genetics; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; neoplasm /cancer vaccine; oncology nursing; paclitaxel; pathology; prostate neoplasms; psychology; quality of life; respiratory neoplasm; tamoxifen; tissue resource /registry; weight loss

DESCRIPTION (adapted from the applicant's abstract): Mount Sinai intends to continue its vigorous participation in activities of the Cancer and Leukemia Group B. We will commit intellectual and patient resources to research in leukemia, lymphomas, breast cancer, respiratory cancers, gastrointestinal cancer, prostate cancer, transplantation and companion studies. These clinical undertakings involve psycho-oncology, pathology, cytogenetics, immunology and epidemiology. Various members of the Mount Sinai faculty serve as Study Chairs, and bring some of their pilot observations to Group consideration. Our efforts are particularly focused on breast cancer, myelodysplastic syndrome and innovations in chemotherapy. The objectives of the Group are to discover and validate effective treatments for the cure and long term palliation of cancer. Mount Sinai is wholeheartedly committed to these objectives and will devote energy to make the most effective studies available to the Group for research purposes. We will participate in single and multi-disciplinary trials, Phase I, II, III and will contribute specimens to the Group's correlative science studies. We will conduct scientific inquiries on Group specimens. Mount Sinai will coordinate the studies of Cooperative Group Outreach Program (CGOP) participants, and serve as a research base for Community Clinical Oncology Program (CCOP) institutions. With these associated investigators in 12 affiliated institutions, Mount Sinai plans to participate in all Group activities.

描述（改编自申请人的摘要）：西奈山打算 继续大力参与癌症和白血病活动 B组。我们将提出智力和患者资源来研究 白血病，淋巴瘤，乳腺癌，呼吸癌，胃肠道 癌症，前列腺癌，移植和伴侣研究。 这些 临床事业涉及心理肿瘤，病理学，细胞遗传学， 免疫学和流行病学。 西奈山的各个成员 用作学习椅，并将一些试点观察带到小组 考虑。 我们的努力尤其专注于乳腺癌， 骨髓增生综合征和化学疗法的创新。 目标的目标 该小组将发现并验证治愈的有效治疗方法 癌症的长期抚慰。 西奈山全心全意地致力于 这些目标，并将投入精力来进行最有效的研究 用于研究目的。 我们将参加单身 和多学科试验，第一阶段，II，III，将贡献 该小组相关科学研究的标本。 我们将进行 对小组标本的科学询问。 西奈山将协调 合作集团外展计划（CGOP）参与者的研究，并为 作为社区临床肿瘤学计划（CCOP）的研究基础 机构。 这些相关的研究人员有12个附属 机构西奈山计划参加所有小组活动。